Clinical trial · Interventional
Effect of Intrathecal Morphine, Dexmedetomidine or Both in Combination to Bupivacaine on Immunity
Effect of Intrathecal Morphine, Dexmedetomidine or Both in Combination to Bupivacaine on Immunity in Patients Undergoing Major Abdominal Cancer Surgeries
NCT03024957CI-TRIAL-00049418unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
this work aims to investigate the effect of intrathecal administration of Morphine, Dexmedetomidine or both in combination on cellular immunity and cytokine production in patients undergoing major abdominal cancer surgeries.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Immune System Suppression | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bupivacaine | Drug | — | UNRESOLVED |
| Dexmedetomidine | Drug | — | UNRESOLVED |
| Morphine Sulfate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Dexmedetomidine group
- description
- patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine in 1 mL volume intrathecally.
- interventionNames
- Drug: Dexmedetomidine
- Drug: Bupivacaine
- type
- ACTIVE_COMPARATOR
- label
- Morphine group
- description
- patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 0.5 mg morphine sulphate in 1 mL volume intrathecally.
- interventionNames
- Drug: Morphine Sulfate
- Drug: Bupivacaine
- type
- ACTIVE_COMPARATOR
- label
- Dexmedetomidine + morphine group
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * ASA I-II patients scheduled for major abdominal cancer surgeries Exclusion Criteria: * patients with known allergy to the study drugs, * significant cardiac, respiratory, renal or hepatic disease, * drug or alcohol abuse, * psychiatric illness that would interfere with perception and assessment of pain.
References
Publications (0)
Data not yet available
No reference posted for this study.